

VGI Health Technology Limited – Update on NAFLD/NASH Phase II Clinical Study

Sydney, New South Wales, 19 December 2022 – VGI Health Technology Limited (**NSX:VTL**) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (**Invictus**), has now recruited and commenced dosing of 10 patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (**NAFLD**)/Non-Alcoholic SteatoHepatitis (**NASH**).

A total of 80 patients will be recruited and dosed for this study which is a randomised, double-blind, placebo-controlled Phase II clinical study on **NAFLD/NASH** to analyse the efficacy and safety of IVB001, a drug candidate based on the non-invasive and direct delivery of tocotrienols using **Invictus'** patented transmucosal delivery platform.

This study is currently recruiting across 6 sites in Australia: Gallipoli Medical Research Foundation in Queensland, The John Hunter Hospital and Concord Hospital in New South Wales, The Royal Melbourne Hospital in Victoria, The Royal Adelaide Hospital in South Australia and the Fiona Stanley Hospital in Western Australia.

NAFLD/NASH is a difficult and intractable disease to treat and there are currently no treatments approved by major regulatory bodies such as the Therapeutic Goods Administration here in Australia or the Food and Drug Administration in the US. **Invictus'** **NAFLD/NASH** drug candidate, IVB001, has the potential to address several aspects of this challenging disease including the steatosis (gathering of fat in liver cells), the inflammation caused by the steatosis and the fibrosis (scarring) resulting from the inflammation. There is strong evidence from clinical studies conducted by other groups on orally-delivered tocotrienols which show promising signs of efficacy against **NAFLD/NASH** and **Invictus** is of the view that its transmucosal delivery platform would enhance this efficacy.

Dr David Kingston, the Chief Scientific Officer of VTL, said “We commenced recruitment of patients for this study in July, with the first patient being recruited in September and the first patient dosed with our drug candidate IVB001 in October. Now we are very pleased to end the year with having recruited 13% of our target patient numbers and we look forward to continuing to progress this study in the New Year”.

For more information please contact:

Dr Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Mrs Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp